We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The effectiveness of long‐acting injectable antipsychotics versus oral antipsychotics in the maintenance treatment of outpatients with chronic schizophrenia.
- Authors
Fang, Su‐Chen; Liao, Ding‐Lieh; Huang, Cheng‐Yi; Hsu, Chun‐Chi; Cheng, Shu‐Li; Shao, Yu‐Hsuan J.
- Abstract
Objective: To compare the psychiatric service utilization between patients who only received long‐acting injectable antipsychotics (LAIAs) and those who only received oral antipsychotics (OAPs) in the maintenance treatment of chronic schizophrenia. Methods: We constructed a cohort of chronic schizophrenia patients who underwent maintenance treatment from the Taiwan National Health Insurance Research Database in 2011 and followed these patients for 12 months. We included patients who had been diagnosed with schizophrenia for at least 3 years, were not hospitalized in 2011, and had received 1 year of maintenance treatment. Inverse probability of treatment weighting logistic, linear, and negative binomial regression models were used to estimate associated psychiatric services utilization and adjust for covariate imbalances between the LAIAs and OAPs groups. Results: Among 40,194 patients, 948 (2.36%) received only LAIAs and 39,246 (97.64%) received only OAPs. Compared with those who received only OAPs, the sole LAIAs users were associated with a lower percentage of psychiatric hospitalization (8.4% and 5.8%, respectively; odds ratio: 0.63, p <.01), shorter lengths of hospitalization days (82.8 and 65.9, respectively; coefficient [b]: −16.87, p =.03), and fewer emergency room visits (2.3 and 1.8, respectively; b: −0.24, p <.01) per patient. Conclusions: Chronic schizophrenia patients who received only LAIs had a lower risk of disease relapse and a reduction in psychiatric service utilization than those receiving only OAPs.
- Subjects
AMISULPRIDE; MENTAL health services; ANTIPSYCHOTIC agents; SCHIZOPHRENIA; PSYCHIATRIC hospital care; DISEASE relapse
- Publication
Human Psychopharmacology: Clinical & Experimental, 2020, Vol 35, Issue 3, p1
- ISSN
0885-6222
- Publication type
Article
- DOI
10.1002/hup.2729